NZOZ Vita Diabetica Małgorzata Buraczyk
- Address
- ul. sw. Rocha 12A lok. 5, 6 15-879 Bialystok, Poland
NZOZ Vita Diabetica Małgorzata Buraczyk - Diabetic Gastroparesis Research Center
NZOZ Vita Diabetica Małgorzata Buraczyk is a specialized clinical research facility focused on diabetes-related complications and gastrointestinal disorders. The center demonstrates particular expertise in investigating treatments for gastroparesis, a condition characterized by delayed stomach emptying that significantly impacts patients' quality of life.
- Diabetic gastroparesis treatment development and therapeutic optimization
- Novel pharmacological interventions for gastrointestinal motility disorders
- Safety and efficacy evaluation of prokinetic medications
The center's research portfolio includes phase clinical trials evaluating innovative treatments for both diabetic and idiopathic gastroparesis. With a focus on optimizing therapeutic dosing and assessing long-term safety profiles, NZOZ Vita Diabetica contributes to advancing treatment options for patients suffering from chronic gastrointestinal complications associated with diabetes and other underlying conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Vita Diabetica Małgorzata Buraczyk
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Insulin Glargine | 1 | Unknown | 2024-04-12 | 2024-04-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.